Clinical Trials List
Protocol NumberCDRB436J12301
Active
2021-09-06 - 2027-08-30
Phase III
Recruiting2
ICD-10C73
Malignant neoplasm of thyroid gland
ICD-10E31.22
Multiple endocrine neoplasia [MEN] type IIA
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9193
Malignant neoplasm of thyroid gland
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 楊舜如 Division of Hematology & Oncology
- Liu Yi-Sheng Division of Radiology
- Shang-Hung Chen Division of Hematology & Oncology
- 陳婉如 Division of Ophthalmology
- 洪崇傑 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
17 participants
-
Global
150 participants
